Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Wenna Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-1209-7872; OpenAlex author ID A5104099349. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper · 2026: 1 paper

Papers 16

  1. Chemotherapy Reawakens Dormant Disseminated Pancreatic Cancer Cells in the Liver by Promoting Senescent Hepatocyte-Induced Neutrophil Extracellular Traps. Co-author DOI 10.1158/0008-5472.can-26-0151↗
  2. Peripheral blood neutrophil-to-lymphocyte ratio as a prognostic marker and its association with the tumor-immune microenvironment in pancreatic cancer: a retro… Co-author DOI 10.21037/jgo-2025-283↗
  3. KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability. Co-author DOI 10.1007/s00018-024-05442-6↗
  4. Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2+ Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy. Co-author DOI 10.1053/j.gastro.2024.02.046↗
  5. CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-l… Co-author DOI 10.1136/gutjnl-2024-332371↗
  6. Solute carrier family 16 member 1 as a potential prognostic factor for pancreatic ductal adenocarcinoma and its influence on tumor immunity. Co-author DOI 10.21037/jgo-24-147↗
  7. SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation. Co-author DOI 10.1136/gutjnl-2022-327492↗
  8. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Co-author DOI 10.1186/s13046-023-02671-8↗
  9. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. Co-author DOI 10.1136/gutjnl-2020-321952↗
  10. Leukemia inhibitory factor is a novel biomarker to predict lymph node and distant metastasis in pancreatic cancer. Co-author DOI 10.1002/ijc.33291↗
  11. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2020.0516↗
  12. Aberrant lactate dehydrogenase A signaling contributes metabolic signatures in pancreatic cancer. Co-author DOI 10.21037/atm-21-295↗
  13. Pancreatic stellate cells regulate branched-chain amino acid metabolism in pancreatic cancer. Co-author DOI 10.21037/atm-21-761↗
  14. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. First author DOI 10.1084/jem.20180749↗
  15. ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin. First author DOI 10.1158/0008-5472.can-16-2170↗
  16. Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms17060799↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tianxing Zhou · 8 shared papers, 2019–2026 · strength 1.24
  2. Jing Liu · 8 shared papers, 2019–2024 · strength 1.15
  3. Jihui Hao · 8 shared papers, 2017–2026 · strength 1.10
  4. Chongbiao Huang · 8 shared papers, 2016–2024 · strength 0.90
  5. Li Ren · 5 shared papers, 2021–2025 · strength 0.80
  6. Tiansuo Zhao · 6 shared papers, 2017–2024 · strength 0.71
  7. Yongjie Xie · 5 shared papers, 2022–2024 · strength 0.71
  8. Duo Zuo · 4 shared papers, 2021–2025 · strength 0.70
  9. Shengyu Yang · 6 shared papers, 2017–2024 · strength 0.69
  10. Song Gao · 5 shared papers, 2019–2024 · strength 0.62
  11. Xiuchao Wang · 5 shared papers, 2017–2024 · strength 0.55
  12. Lu Qiao · 3 shared papers, 2021–2024 · strength 0.48
  13. Meng Wang · 2 shared papers, 2024 · strength 0.40
  14. Rui Liu · 2 shared papers, 2021–2026 · strength 0.37
  15. Danqi Fu · 3 shared papers, 2019–2023 · strength 0.34
  16. Xiufeng Zhang · 2 shared papers, 2023–2024 · strength 0.29
  17. Liangliang Wu · 1 shared paper, 2026 · strength 0.25
  18. Chuntao Gao · 1 shared paper, 2026 · strength 0.25
  19. Shangheng Shi · 1 shared paper, 2026 · strength 0.25
  20. Kentaro Inamura · 1 shared paper, 2025 · strength 0.25
  21. Jing Li · 1 shared paper, 2025 · strength 0.25
  22. Jiayi Wang · 1 shared paper, 2025 · strength 0.25
  23. Elisa Giovannetti · 1 shared paper, 2025 · strength 0.25
  24. Li Ren · 1 shared paper, 2024 · strength 0.20
  25. Abhinav V. Reddy · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.